Abstract TAR DNA-binding protein of 43 kDa (TDP-43) is a major component of the pathological inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy, also called FTLD with ubiquitin-positive, taunegative inclusions (FTLD-U), and motor neuron disease (MND). TDP-43 is predominantly expressed in the nucleus and regulates gene expression and splicing. In FTLD with TDP-43 proteinopathy, neuronal inclusions present variably as cytoplasmic inclusions (NCIs), dystrophic neurites (DNs), and intranuclear inclusions (NIIs), leading to a fourfold neuropathological classification correlating with genotype. There have been few fine structural studies of these inclusions. Thus, we undertook an immunoelectron microscopic study of FTLD with TDP-43 proteinopathy, including sporadic and familial cases with progranulin (GRN) mutation. TDP-43-immunoreactive inclusions comprised two components: granular and filamentous. Filament widths, expressed as mean (range) were: NCI, 9 nm (4-16 nm); DN, 10 nm (5-16 nm); NII, 18 nm (9-50 nm). Morphologically distinct inclusion components may reflect the process of TDP-43 aggregation and interaction with other proteins: determining these latter may contribute towards understanding the heterogeneous pathogenesis of FTLD with TDP-43 proteinopathy.
Introduction
TAR DNA-binding protein of 43 kDa (TDP-43) is a major component of the inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy, also called FTLD with ubiquitin-immunoreactive, tau-negative inclusions (FTLD-U), FTLD-U with motor neuron disease (FTLD-MND), and MND (Cairns et al. 2007a; Neumann et al. 2006) . TDP-43 is also being recognised increasingly as a variable component of inclusions of other neurodegenerative diseases including Alzheimer's disease (AD) (Amador-Ortiz et al. 2007 ), corticobasal degeneration (Uryu et al. 2008) , dementia with Lewy bodies (Higashi et al. 2007; Nakashima-Yasuda et al. 2007 ), ALS/dementia-parkinsonism of Guam , and hippocampal sclerosis (Amador-Ortiz et al. 2007 ). In FTLD with TDP-43 proteinopathy, three types of neuronal TDP-43-immunoreactive inclusions have been described: neuronal cytoplasmic inclusions (NCIs), dystrophic neurites (DNs) and neuronal intranuclear inclusions (NIIs). In FTLD-MND, TDP-43 aggregates may be present, additionally, in glial cells (Brandmeir et al. 2008; Seelaar et al. 2007 ), most commonly in oligodendrocytes, but the inclusions in FTLD-MND are distinct from the Papp-Lantos bodies of multiple system atrophy where the major pathological protein is a-synuclein (Jellinger 2003) ; in contrast, the glial cytoplasmic inclusions (GCIs) of FTLD-MND are TDP-43-immunoreactive and a-synuclein-negative. In addition to the distinct immunohistochemical profile of the inclusions of FTLD and MND with TDP-43 proteinopathy, this group of diseases is characterised by a unique biochemical signature: TDP-43 forms relatively insoluble aggregates that are ubiquitinated and hyperphosphorylated and cleaved to generate abnormal C-terminal fragments which may be visualised by immunoblotting (Neumann et al. 2006) .
TDP-43 was initially cloned and characterised as a protein that binds to human immunodeficiency virus type-1 (HIV1) TAR DNA-sequence motifs (Ignatius et al. 1995) . It is predominantly expressed within the nucleus and is encoded by the TAR DNA-binding protein (TARDBP) gene on chromosome 1. The functional repertoire of TDP-43 is incompletely known but includes regulation of gene expression and mRNA splicing . TDP-43 has two mRNA-binding domains, a heterogeneous ribonucleoprotein (hnRNP) binding site, and nuclear localisation and export motifs. TDP-43 has been implicated in the pathogenesis of cystic fibrosis via transcriptional repression and exon skipping (Buratti et al. , 2005 Zuccato et al. 2004) .
TDP-43 proteinopathy is clinically heterogeneous and includes the spectrum of phenotypes encompassed by FTLD, FTLD-MND and MND; additionally, the memory deficits more commonly seen in dementia of the Alzheimer's type, parkinsonism, and corticobasal syndrome may be present. In addition to sporadic cases, there is also molecular genetic heterogeneity. FTLD with TDP-43 proteinopathy may be caused by mutations in several genes: FTLD with progranulin (GRN) mutation, FTLD with valosin-containing protein (VCP) mutation, and FTLD-linked chromosome 9 (Cairns et al. 2007a) . Recently, mutations were reported in the TARDBP gene in autosomal dominantly inherited MND Kabashi et al. 2008; Sreedharan et al. 2008 ). These observations indicate that abnormal TDP-43 alone is sufficient to cause neurodegeneration.
Although there have been several studies describing the morphology and immunoreactive profile of inclusions in FTLD with TDP-43 proteinopathy at the light microscope level (Arai et al. 2006; Cairns et al. 2007b; Davidson et al. 2007; Neumann et al. 2006) , there have been only isolated and limited reports of the fine structure of the inclusions in the TDP-43 proteinopathies (Amador-Ortiz et al. 2007; Cairns et al. 2007b; Hasegawa et al. 2008) . Therefore, to further characterise the inclusions of FTLD with TDP-43 proteinopathy, we have undertaken an immunoelectron microscopic study and show that there are, variably, two components to the inclusions: granular material and filamentous or fibrillary material. The presence of these different components probably reflects the process of TDP-43 aggregation and the presence of partner proteins within the granular regions of inclusions in FTLD with TDP-43 proteinopathy.
Materials and methods
Brain tissue collection, processing, and neuropathological assessment Frozen and formalin-fixed, paraffin wax-embedded brain tissues from clinically and neuropathologically wellcharacterised cases of FTLD with TDP-43 proteinopathy (Table 1) were obtained from the Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MI, USA. Tissues from the middle frontal gyrus of six cases were used for this study, including two cases of FTLD with GRN mutation which we reported previously (Mukherjee et al. 2006 (Mukherjee et al. , 2008 . The pattern and distribution of inclusions in these cases was previously assessed using the Consensus Criteria for Frontotemporal Lobar Degeneration: three cases were FTLD-U type 2 and three cases were FTLD-U type 3 (Cairns et al. 2007a) . Tissue was removed according to Washington University Local Ethics Committee guidelines and informed consent for brain donation was obtained from the next-of-kin. Histology and immunohistochemistry Tissue blocks were taken from the middle frontal gyrus. Antigen retrieval was performed by heating sections in a solution of 0.5% ethylenediaminetetraacetic acid (EDTA) in 100 mmol/L Tris, pH 7.6 at 100°C for 10 min. Immunohistochemistry (IHC) was undertaken on 6-10 lm-thick sections prepared from formalin-fixed, paraffin waxembedded tissue blocks using the avidin-biotin complex detection system (Vector Laboratories, Burlingame, CA, USA) and the chromagen 3,3 0 -diaminobenzidine (DAB) and sections were counterstained with haematoxylin. Antibodies used included those that recognise ubiquitin (1:2,000; Dako UK Ltd., Ely, UK) and TDP-43 (1:2,000, Proteintech Inc., Chicago, IL, USA). The antibodies used in this study are well-characterised and have been used previously to demonstrate epitopes of ubiquitin and TDP-43 in sporadic and familial cases of FTLD with TDP-43 proteinopathy (Cairns et al. 2007b) . After the completion of this study, a disease-specific phosphorylation-dependent anti-TDP-43 antibody was reported (Hasegawa et al. 2008) , but this was not available for the use in the experiments described here.
Tissue preparation for transmission electron microscopy Frozen brain tissue stored at -70°C was brought to -20°C. The grey matter was identified, dissected, and samples placed directly into a cold (4°C) solution of 4% (w/v) formaldehyde and 0.1% (v/v) glutaraldehyde (vacuumdistilled) in phosphate-buffered saline (PBS). The following procedures were carried out at 4°C. After 18 h of fixation, the samples were rinsed thoroughly in PBS then dehydrated in an ethanol series and embedded in Unicryl resin (British BioCell International, Cardiff, UK) as previously described (Thorpe et al. 2001) .
Primary antibodies and secondary probes
Affinity-purified polyclonal rabbit IgGs, raised against human recombinant TDP-43 protein and ubiquitin, were obtained from Proteintech Group, Inc. (Chicago, IL, USA) and Dako UK Ltd. (Ely, UK), respectively. A 10 nm gold particle-conjugated goat anti-rabbit IgG secondary probe (GaR10) was obtained from British BioCell International (Cardiff, UK).
Immunogold labelling transmission electron microscopy
We used established methods to perform immunogold transmission electron microscopy (TEM) (Thorpe 1999) .
A modified PBS, pH 8.2 containing 1% BSA, 500 ll/L Tween-20, 10 mM NaEDTA and 0.2 g/L NaN 3 (henceforward termed PBS?) was used throughout all the following procedures for all dilutions of antibodies and gold probes. For each of the six cases, three separate blocks of tissue were sectioned for immunogold labelling. Multiple serial sections were cut and collected on TEM support grids for immunolabelling. Serial sections were initially blocked in normal goat serum (1:10 in PBS?) for 30 min ambient. To investigate the fine structure of the inclusions, sections were single-labelled with anti-TDP-43 (2 lg/ml IgG final concentration) and anti-ubiquitin (25 lg/ml IgG final concentration). To determine the specificity of the anti-TDP-43 and anti-ubiquitin antibodies, control incubations were run using non-immune rabbit serum at IgG concentrations matching the concentrations of the primary antibodies.
After 3 9 2 min PBS? rinses, the sections were immunolabelled in GaR10 (1:10) for 1 h ambient. Sections were subsequently rinsed in PBS? (3 9 10 min) and distilled water (4 9 5 min). All immunogold labelled thin sections were post-stained in 0.5% (w/v) aqueous uranyl acetate for 1 h and examined in a Hitachi-7100 TEM at 100 kV. The sections were systematically thoroughly scanned for pathology and images acquired digitally with an axially mounted (2 9 2 K pixel) Gatan Ultrascan 1000 CCD camera (Gatan UK, Oxford, UK).
Results

Immunohistochemistry
At the light microscope level, TDP-43-immunoreactive inclusions were detected at three sites: NCIs, DNs, and rare NIIs (Fig. 1a , b, c); no glial inclusions were seen. In the six cases examined, NCIs and DNs were the most frequent morphological type; NIIs were rare in the familial cases of FTLD with GRN mutation and not seen in any of the sporadic cases. As previously reported, NCIs were present in neurons that lacked nuclear TDP-43-immunoreactivity, indicating a redistribution of the normally predominantly nuclear protein to abnormal cytoplasmic aggregates (Fig. 1c) .
Neuronal nuclear localisation of TDP-43
Immunoelectron TEM of normal brain neurons revealed a predominantly nuclear localisation of TDP-43 consistent with that seen by IHC with the light microscope. TDP-43 labelling was preferentially associated with euchromatin regions within the nucleus (Fig. 2a, b) .
Fine structural analysis of the neuronal inclusions of frontotemporal lobar degenerationNeuronal cytoplasmic inclusions By TEM, TDP-43-labelled NCIs appeared typically oval or round and lacked a limiting membrane (Fig. 3a, d , respectively). The inclusions generally contained admixed granular and filamentous components (Fig. 3b, c) . Some inclusions of a very granular appearance were more heavily immunolabelled with anti-TDP-43 antibodies (Fig. 3d) . More rarely, the filamentous component predominated, although TDP-43 labelling was generally heavier over the more densely stained, granular regions of the inclusion ( Fig. 3e, f ; Table 3 ). Dispersed filaments within the NCIs had a mean diameter of 9 nm (range 4-16 nm; Table 2 ). Serial sections labelled with anti-ubiquitin and anti-TDP-43 antibodies revealed that the NCIs contained both ubiquitin (data not shown) and TDP-43 epitopes.
The TDP-43-positive inclusion-bearing neurons had very low levels of TDP-43 labelling within their nuclei, consistent with that observed with the light microscope (Fig. 1c ). This loss of nuclear labelling was also observed in neurons with no apparent inclusion, most likely explained by only partial inclusion of the neuron in the plane of section. There was also labelling of loosely defined aggregates with anti-TDP-43 antibodies in perikaryal regions, a phenomenon which may be an early stage in the evolution of TDP-43-immunoreactive inclusions. This redirection of TDP-43 to the cytoplasm may be the harbinger of ubiquitination, proteolytic cleavage, and eventual aggregation to form a relatively insoluble protein aggregate. For example, Fig. 4a and b show two neurons of similar appearance, with lipofuscin accumulations, and cytoplasm of a normal appearance; however, there were high levels of TDP-43 labelling in the nucleus and low levels in the cytoplasm of the neuron in Fig. 4a , whereas, the neuron in Fig. 4b , showed cytoplasmic relocation of TDP-43 protein (Fig. 4b) , with concurrent low levels Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration 1665 filamentous structure (Fig. 5) ; these filaments ranged in width from 5 to 16 nm, with a mean of 10 nm (Table 2) . These latter DNs often appeared as very short processes, presumably reflecting their partial appearance in the plane of section. Less frequently, TDP-43-positive processes were more swollen and dystrophic (*1-5 lm wide; Fig. 6 ). These DNs were characterised by either a dense, amorphous, granular content (Fig. 6a, b) or, more rarely, a filamentous component intermingled with the granular component ( Fig. 6c, d ; Table 3 ). In these mixed structures, more intense TDP-43 labelling was associated with the granular component (Fig. 6d) . These swollen, TDP-43-positive DNs were also heavily ubiquitinated as demonstrated by labelling of serial sections labelled with anti-ubiquitin antibodies (Fig. 6e) . 
Neuronal intranuclear inclusion
NIIs are typically absent in FTLD with TDP-43 proteinopathy type 2, and are typically sparsely observed by light microscopy in type 3 cases (Cairns et al. 2007a) . They are most frequently seen in cases of FTLD with valosin-containing protein (VCP) gene mutations (Cairns et al. 2007a ), but none of these cases was available for immunogold TEM. Many grids were examined before we observed one well-defined NII by TEM (Fig. 7) . The NII was initially identified by the presence of abnormal fibrils within the nucleus. Interestingly, this type of NII may not be immediately recognisable as an NII with the light microscope because the overall intensity of TDP-43 labelling was similar to that of normal brain nuclei. The recently described phosphorylation-dependent anti-TDP-43 antibody (Hasegawa et al. 2008) should greatly facilitate the identification of nuclear inclusions. The mean fibril diameter was 18 nm (range 9-50 nm). The broadest filaments were present in bundles, which were aligned with the nuclear envelope (Fig. 7a) , and were relatively intensely labelled with anti-TDP-43 antibodies (Fig. 7b, d ). These latter were at the periphery of the inclusion and encircled a region of medium-and fine-diameter fibrils that were associated with fine granular material. This granular material and the finer filaments were relatively lightly labelled ( Fig. 7c ; Tables 2, 3) .
Discussion
TDP-43 has recently been added to the list of proteins that are misfolded and progressively aggregate to form the hallmark pathological inclusions of several neurodegenerative diseases (Armstrong et al. 2008) . TDP-43 proteinopathy is the most recent molecular pathology to be added to this list. TDP-43 is the major pathological protein of the ubiquitin-positive, tau-and a-synuclein-negative inclusions of FTLD-U, FTLD-MND and MND (Neumann et al. 2006) , and a variable component of the inclusions of an increasing number of other diseases, including AD (Amador-Ortiz et al. 2007 ), corticobasal degeneration (Uryu et al. 2008) , dementia with Lewy bodies (Higashi et al. 2007; NakashimaYasuda et al. 2007 ) ALS/dementia-parkinsonism of Guam Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration 1667 , and hippocampal sclerosis (AmadorOrtiz et al. 2007 ). The importance of TDP-43 was recently underscored by the discovery of missense mutations in the TARDBP gene Kabashi et al. 2008; Sreedharan et al. 2008) . These molecular genetic defects in affected individuals with autosomal dominantly inherited disease confirm that abnormal TDP-43 is sufficient to cause TDP-43 proteinopathy, neurodegeneration, and clinical symptoms. The biochemical signature of this group of diseases, called TDP-43 proteinopathies, is sarkosylinsoluble, urea-soluble TDP-43 which is ubiquitinated and forms abnormal C-terminal cleavage products which are also hyperphosphorylated (Arai et al. 2006; Hasegawa et al. 2008; Neumann et al. 2006) . Theses biochemical changes correlate with the brain areas with TDP-43-immunoreactive aggregates. Insights into the in vivo aggregation and toxicity of TDP-43 have recently been acquired from a yeast model of TDP-43 proteinopathy (Johnson et al. 2008) . Increased (full-length) TDP-43 expression resulted in cytoplasmic aggregation of the protein in the form of inclusions and their data established that TDP-43 had a cytotoxic effect in vitro. Expression of a range of DNA constructs also showed that the C-terminal region and one of the two RNA-recognition motifs (RRM2) were required to produce both cytoplasmic aggregation and a cytotoxic effect of TDP-43; these data, together with the causative mutations in TARDBP, implicate TDP-43 directly in the pathogenesis of TDP-43 proteinopathy.
In this study, we investigated the fine structure of three types of neuronal inclusions of sporadic and familial FTLD with TDP-43 proteinopathy using immunogold TEM. The NCIs and DNs of sporadic FTLD with TDP-43 proteinopathy were similar to those seen in familial FTLD with GRN mutation. Despite extensive searching of multiple grids, too few NIIs were identified to make a comparison between these two groups. To date, there have been very few ultrastructural studies of the inclusions of FTLD with TDP-43 proteinopathy. Amador-Ortiz et al. 2007 investigated TDP-43 in FTLD with TDP-43 proteinopathy within the setting of hippocampal sclerosis and AD. They reported, but showed no data of, TDP-43 epitopes within (Hasegawa et al. 2008) , comparable to the filament width reported in this study.
In a large immunohistochemical investigation of TDP-43 in sporadic and familial cases of FTLD with ubiquitinimunoreactive, tau-negative inclusions, TEM images revealed TDP-43 epitopes in a hippocampal NCI and a DN from the temporal lobe: the NCIs were predominantly granular with a minor filamentous component; in contrast, DNs were more filamentous in appearance (Cairns et al. 2007b) .
In this report, we have extended our earlier studies (Cairns et al. 2007b ) to include a detailed investigation of the fine structure of the neuronal inclusions of FTLD with TDP-43 proteinopathy. Initial observations of normal agematched control cases showed the expected predominantly nuclear localisation of TDP-43; there was a similar TDP-43 distribution in unaffected neurons within the FTLD with TDP-43 proteinopathy cases. Nuclear TDP-43 immunolabelling was preferentially associated with regions of euchromatin, which is consistent with its known role in transcriptional regulation .
At the ultrastructural level, the inclusions within neuronal cytoplasmic (NCIs), neuritic (DNs) and nuclear compartments (NII) comprised both granular and fibrillar components. Within NCIs these granular and filamentous components were admixed, with the former being more heavily TDP-43-immunoreactive. Conversely, in the finer TDP-43-immunoreactive neurites and in the NII frequent TDP-43 epitopes were identified with fibrils. Some of these filaments were broader in the nuclear compartment than any TDP-43-positive filaments observed in the NCIs or DNs. Interestingly, we showed previously that the filaments of NIIs of neuronal intermediate filament inclusion disease (NIFID) were broader than those of the NCIs (20 nm compared with 10 nm; Mosaheb et al. 2005) . Whilst the granular component of the NII of FTLD with TDP-43 proteinopathy was relatively minor, this granular component predominated within most of the mature, swollen DNs and contained frequent TDP-43 epitopes.
The TEM ultrastructural method used in this study has not only elucidated the fine structure of the neuronal inclusions, but has also provided an insight into the process of TDP-43 aggregation which is not discernible with the light microscope. For example, we observed neurons with low levels of nuclear TDP-43 and significant perikaryal TDP-43 positivity over areas of cytoplasm of a normal appearance indicating that the redistribution of TDP-43 takes place at an early stage in the disease process, rather than being secondary to accumulation with other interacting proteins within the cytoplasm. This redistribution of TDP-43 is reminiscent of that of another nuclear protein, Pin1, which has multiple cellular roles, including transcriptional regulation, which we have previously shown to be redistributed to the cytoplasm of neurons in several FTLD entities (Thorpe et al. 2004 ). The loss of nuclear function of TDP-43 might be the stimulus for activation of an apoptotic cascade as has been suggested for Pin1 nuclear depletion. Further studies are required to elucidate the significance of translocation of TDP-43 between the nucleus and cytoplasm.
In addition, we have identified a predominantly filamentous NII. Importantly, this inclusion is unlikely to have been apparent by light microscopy as the overall level of nuclear TDP-43 was not significantly higher than of normal neuronal nuclei. TDP-43 immunolabelling specifically aligned along the broadest fibrils of the NII, but only at intermittent points. As the finer filaments were weakly TDP-43-immunoreactive, this suggests that TDP-43 may be recruited following a prior aggregation step, or TDP-43 is post-translationally modified differently in the nucleus compared to the cytoplasm, resulting in an altered immunoreactive profile.
Overall, this work contributes to our understanding of the ultrastructural morphology of TDP-43 inclusions, and complements and extends upon other such data published whilst this manuscript was under review (Lin and Dickson 2008) . The full functional repertoire of TDP-43 and the identities of its interacting proteins are incompletely understood. The elucidation of the normal physiological role of TDP-43 is likely to illuminate possible mechanisms of pathogenesis. Also, the future use of disease-specific anti-TDP-43 antibodies and those of its partner proteins or nucleic acids should provide insights into the abnormal accumulation of TDP-43 in the nucleus, cytoplasm and neurite of the degenerating neuron of FTLD with TDP-43 proteinopathy.
